目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.3.3 CURRENCY CONSIDERED FOR THE STUDY
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 KEY DATA FROM SECONDARY SOURCES
2.1.2 PRIMARY DATA
2.1.2.1 KEY DATA FROM PRIMARY SOURCES
2.1.2.2 KEY INDUSTRY INSIGHTS
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.7 RISK ASSESSMENT
2.8 IMPACT OF ECONOMIC RECESSION

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW
4.2 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT (2022)
4.3 RESPIRATORY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL MIX
4.5 RESPIRATORY DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 INDUSTRY TRENDS
5.4 TARIFF AND REGULATORY LANDSCAPE
5.4.1 REGULATORY ANALYSIS
5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.5 ECOSYSTEM/ MARKET MAP
5.6 VALUE CHAIN ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.2 COMPLIMENTARY TECHNOLOGIES
5.7.3 ADJACENT TECHNOLOGIES
5.8 PATENT ANALYSIS
5.9 TRADE ANALYSIS
5.1 CASE STUDY ANALYSIS
5.11 PORTER’S FIVE FORCES ANALYSIS
5.12 SUPPLY CHAIN ANALYSIS
5.13 KEY CONFERENCES & EVENTS DURING 2023-2024
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS & BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 PRICING ANALYSIS
5.15.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE
5.15.2 AVERAGE SELLING PRICE TREND, BY REGION
5.16 UNMET NEEDS PERTAINING TO RESPIRATORY DIAGNOSTIC DEVICES
5.17 APPLICATION OF AI INTEGRATION IN RESPIRATORY DIAGNOSTIC DEVICES
5.18 REIMBURSEMENT SCENARIO IN RESPIRATORY DIAGNOSTICS MARKET
5.19 ADJACENT MARKET ANALYSIS

6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021-2029 (USD MILLION)
6.1 INTRODUCTION
6.2 INSTRUMENTS & DEVICES
6.3 ASSAYS & REAGENTS
6.4 SERVICES & SOFTWARE

7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2029 (USD MILLION)
7.1 INTRODUCTION
7.2 MECHANICAL TESTS
7.2.1 PULMONARY FUNCTION TESTS
7.2.1.1 SPIROMETRY
7.2.1.2 PEAK FLOW TEST
7.3 OSA DIAGNOSTIC TESTS
7.4 IMAGING TESTS
7.4.1 X-RAY
7.4.2 COMPUTED TOMOGRAPHY
7.4.3 MAGNETIC RESONANCE IMAGING (MRI)
7.4.4 POSITRON EMISSION TOMOGRAPHY (PET)
7.4.5 OTHER IMAGING TESTS
7.5 TRADITIONAL DIAGNOSTIC TESTS
7.5.1 IMMUNODIAGNOSTICS
7.5.2 BIOCHEMICAL TESTS
7.5.3 MICROSCOPY
7.6 MOLECULAR DIAGNOSTIC TESTS
7.6.1 PCR
7.6.2 NUCLEIC ACID AMPLIFICATION TEST
7.6.3 IN SITU HYBRIDIZATION
7.6.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
7.6.5 MICROARRAYS
7.6.6 OTHERS

8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021-2029 (USD MILLION)
8.1 INTRODUCTION
8.2 TUBERCULOSIS
8.3 ASTHMA
8.4 LUNG CANCER
8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
8.6 OTHERS

9 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021-2029 (USD MILLION)
9.1 INTRODUCTION
9.2 HOSPITALS AND CLINICS
9.3 DIAGNOSTICS LABORATORIES
9.4 OTHERS

10 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2021-2029 (USD MILLION)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 RECESSION IMPACT
10.2.2 US
10.2.3 CANADA
10.3 EUROPE
10.3.1 RECESSION IMPACT
10.3.2 GERMANY
10.3.3 UK
10.3.4 FRANCE
10.3.5 ITALY
10.3.6 SPAIN
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 RECESSION IMPACT
10.4.2 JAPAN
10.4.3 CHINA
10.4.4 INDIA
10.4.5 AUSTRALIA
10.4.6 SOUTH KOREA
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 RECESSION IMPACT
10.5.2 BRAZIL
10.5.3 MEXICO
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 RECESSION IMPACT

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 RIGHT TO WIN/KEY STRATEGIES
11.3 REVENUE ANALYSIS FOR TOP FIVE MARKET PLAYERS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX, 2022
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT
11.6 STARTUP/SME EVALUATION MATRIX, 2022
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING
11.7 COMPETITIVE SCENARIO AND TRENDS
11.7.1 PRODUCT LAUNCHES & APPROVALS
11.7.2 DEALS
11.7.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, And Mnm View (Key Strengths/Right To Win, Strategic Choices Made, And Weaknesses And Competitive Threats))
12.1.1 PHILIPS HEALTHCARE
12.1.2 BECTON, DICKINSON & COMPANY
12.1.3 ABBOTT LABORATORIES
12.1.4 THERMO FISHER SCIENTIFIC INC.
12.1.5 BIOMERIEUX
12.1.6 ALERE INC.
12.1.7 BIO-RAD LABORATORIES INC
12.1.8 COSMED
12.1.9 SEEGENE INC.
12.1.10 SDI DIAGNOSTICS
12.1.11 RESMED
12.1.12 SIEMENS HEALTHINEERS
12.1.13 MASIMO CORPORATION
12.1.14 ASTRAZENECA
12.1.15 PERKINELMER
12.1.16 MEDTRONIC
12.1.17 DRÄGERWERK AG & CO. KGAA
12.1.18 NIHON KOHDEN CORPORATION
12.1.19 GETINGE
12.1.20 FISHER & PAYKEL APPLIANCES LTD
12.1.21 GE HEALTHCARE
12.2 OTHER PLAYERS
12.2.1 NONIN MEDICAL INC.
12.2.2 ALLIED MEDICAL
12.2.3 DRIVE DEVILBISS
12.2.4 OMRON
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATIONS OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS